Pharmaceuticals

SSY GROUP

Stone Pharmaceutical's Vitamin B12 Injection Gains Approval for New Specifications from NMPA

Stone Pharmaceutical Group Obtains Pharmaceutical Production Registration Approval from China's National Medical Products Administration

Stone Pharmaceutical Group's Furosemide Approved by National Medical Products Administration

Stone Pharmaceutical Group Reports Weakened Operations in 2025 with a Decline in IV Solution Sales

Stone Pharmaceutical's Upadacitinib Approved by National Medical Products Administration

SSY GROUP released FY2025 Q3 earnings on March 27 (BJT), actual revenue HKD 1.009 B, actual EPS HKD 0.032

SSY GROUP released FY2025 9 Months earnings on March 27, 2026 (BJT), actual revenue HKD 3.156 B, actual EPS HKD 0.1282

SSY GROUP released FY2025 Annual Earnings on March 27 Pre-Market (BJT), actual revenue HKD 4.165 B (forecast HKD 4.458 B), actual EPS HKD 0.1604 (forecast HKD 0.2075)

SSY GROUP released FY2025 Q4 earnings on March 27 Pre-Market (BJT), actual revenue HKD 1.009 B, actual EPS HKD 0.032

SSY GROUP to Release FY2025 Annual Earnings on March 27, Pre-Market (BJT), Forecast Revenue HKD 4.458 B, EPS HKD 0.2075

Stone Pharmaceutical Group's Bumetanide Approved by National Medical Products Administration

Stone Pharma Group Obtains Registration Certificates for Two Medical Devices

Sino-Pharm's Two Raw Materials Approved for Market

StoneRain Pharma Obtains Production License for Sodium Phosphoglycerate Injection

Stone Pharmaceutical Obtains Production Registration Approvals for Acetylcysteine Injection and Compound Sodium Lactate Ringer Injection

Stone Pharmaceutical Group Obtains Approval for Fingolimod Active Pharmaceutical Ingredient Registration

SJM Pharmaceutical's Bilastine and Picosulfate Approved by China's NMPA

Stone Pharmaceutical Obtains Production Registration for Tolterodine Tartrate Extended-Release Capsules

Stone Pharmaceutical Group Obtains Approval for Palmitate Vitamin A Production and Sales

Sino-Uncle Pharmaceutical Group and Stone Pharmaceutical Group Conducted Latest Shareholding Disclosure

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

02005

SSY Group has received regulatory approval in China for Oseltamivir Phosphate capsules, enhancing its antiviral portfolio. The company also secured approvals for Drotaverine Hydrochloride and Metoclopramide tablets, expanding its offerings in gastrointestinal and antispasmodic therapies. These developments position SSY Group to benefit from the demand for flu treatments and strengthen its competitive standing in the generic pharmaceutical market. The latest analyst rating for SSY Group (HK:2005) is a Buy with a price target of HK$5.00.

Tip Ranks

SSY Group Wins Trio of NMPA Approvals, Expanding China Drug Portfolio

SSY Group has received key approvals in China, becoming the first to secure production and registration for a fat-soluble vitamin injection for infants. The company also gained regulatory approvals for metformin hydrochloride tablets and doxazosin mesylate extended release tablets, enhancing its chronic disease portfolio. These developments position SSY Group competitively in the generic drug market. Analysts rate the stock as a Buy with a target price of HK$5.00. SSY Group focuses on developing injectable and oral medications in pediatrics and chronic disease management.

SSY Group Wins Key China Drug Approvals, Expands Chronic and Pediatric Portfolio

01396

02565

02635

03296

02940

02442

01050

03858

00917

GD-HKGBA HLDGS(01396) rose 30.29%, with a trading turnover 255.4 Million HKD, and a year-to-date rose 180.9%. PEGBIO CO-B(02565) rose 13.07%, with a trading turnover 59.8 Million HKD, and a year-to-date fell 59.6%. NUOBIKAN(02635) rose 9.27%, with a trading turnover 47.6 Million HKD, and a year-to-date fell 35.7%.

Top Gainers&Losers

GD-HKGBA HLDGS

PEGBIO CO-B

NUOBIKAN

HUAQIN

WELLCELL HOLD

EASY SMART GP

KARRIE INT'L

JIAXIN INTL RES

QUNABOX GROUP

Top 10 HK Stock Gainers (5.5)

SSY Group Limited has received Chinese production and registration approval for two cardiovascular injectables: Diltiazem Hydrochloride for Injection and Propranolol Hydrochloride Injection. These approvals enhance the company's portfolio in acute cardiovascular care and strengthen its position in China's hospital drug market. The latest analyst rating for SSY Group (HK:2005) is a Buy with a price target of HK$5.00. The company focuses on developing high-quality injectable drugs for critical care in China.

SSY Group Wins Chinese Approvals for Two Cardiovascular Injectables

520500

588130

588860

159506

520880

560600

516930

512290

159859

SSY Group Limited has received approval from China's National Medical Products Administration for its Upadacitinib bulk drug, a JAK-1 inhibitor for treating autoimmune disorders. This marks the third approval for a PRC entity and is expected to enhance SSY's product portfolio in immunology, improving its competitive position in China's growing market for targeted treatments. The stock currently holds a Hold rating with a price target of HK$3.00 and a market cap of HK$7.08B.

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

China Southern Hang Seng Biotech ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

Penghua SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

Huaan Hang Seng Biotech ETF

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng Health Care ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

E Fund Hang Seng SCHK Innovative Drug ETF

SSY Group Wins China Approval for Upadacitinib Bulk Drug

SSY GROUP announced that Sodium Lactate Ringer's Injection (3000ml) and Bumetanide Injection (2ml:1mg) have obtained the drug production registration approval from the National Medical Products Administration of China, both classified as Class 3 chemical drugs, equivalent to passing the consistency evaluation

AASTOCKS

SSY GROUP's two products received production registration approval from the National Medical Products Administration

SSY Group Ltd. reported a significant drop in profit for fiscal 2025, with net profit falling 55.6% to HK$470.64 million due to weak revenues of approximately HK$4.17 billion, a decrease of 27.8% from the previous year. The company announced a cut in its final dividend to HK$0.03 per share, down from HK$0.095, resulting in a total annual dividend of HK$0.08, a 54.3% reduction. Shares were trading at HK$2.420, up 1.26%.

rttnews

SSY Group FY25 Profit Drops On Weak Revenues; Cuts Dividend- Update

SSY Group Profit Halves as Revenue and Margins Slide in Challenging 2025

SSY Group Profit Halves as Revenue and Margins Slide in Challenging 2025

SSY GROUP(02005.HK)

SSY Group Wins Trio of NMPA Approvals, Expanding China Drug Portfolio

SSY Group Wins Key China Drug Approvals, Expands Chronic and Pediatric Portfolio

Top 10 HK Stock Gainers (5.5)

SSY Group Wins Chinese Approvals for Two Cardiovascular Injectables

SSY Group Wins China Approval for Upadacitinib Bulk Drug

SSY GROUP's two products received production registration approval from the National Medical Products Administration

SSY Group FY25 Profit Drops On Weak Revenues; Cuts Dividend- Update

SSY Group Profit Halves as Revenue and Margins Slide in Challenging 2025